PT-141 vs Tadalafil: Desire, Blood Flow and Safety Compared

The core difference in PT-141 vs tadalafil is the system each drug acts on. PT-141 (bremelanotide) is a melanocortin receptor agonist that works on nervous-system pathways tied to sexual desire. Tadalafil, the active ingredient in Cialis, is a PDE5 inhibitor that works on blood flow and supports the physical side of erectile function. They fit different problems, need different safety screens, and neither is right for everyone.

Key takeaways

• PT-141 and tadalafil are not two strengths of the same thing: PT-141 acts on nervous-system pathways tied to desire, while tadalafil acts on blood flow.
• Brand bremelanotide (Vyleesi) is FDA-approved only for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, its label says it is not indicated in men, and compounded PT-141 is not FDA-approved.
• Tadalafil is the active ingredient in Cialis, which is FDA-approved for erectile dysfunction (ED) and the signs and symptoms of benign prostatic hyperplasia (BPH), a noncancerous enlargement of the prostate.
• The safety screens point in opposite directions: PT-141 briefly raises blood pressure, so a clinician screens blood pressure and heart health, while tadalafil combined with nitrates can drop blood pressure to unsafe levels.
• Not everyone qualifies for either, and a licensed clinician decides based on your intake and clinical review.

PT-141 vs tadalafil at a glance

PT-141 targets desire and tadalafil targets blood flow, and nearly every other difference follows from that. Bremelanotide vs tadalafil is the same comparison under the generic name.

Sources for the table: the Vyleesi label, 2024, the Cialis label, 2009 and the tadalafil label on DailyMed.

Compounded medications, including compounded PT-141 and the tadalafil troche, are not FDA-approved. The side-effect figures come from trials of the brand products, not compounded versions. There are no onset, duration, dose or price columns on purpose. Those details belong to your clinician's guidance, pharmacy instructions and the treatment page.

Desire vs blood flow: how each drug works

PT-141 works on the nervous system, not on blood flow. Tadalafil works on blood flow, not on desire.

A melanocortin receptor agonist is a drug that activates melanocortin receptors in the body. That is the label class for bremelanotide (Vyleesi label, 2024). In plain terms, PT-141 acts on nervous-system pathways tied to sexual desire. It does not work by widening blood vessels.

A PDE5 inhibitor blocks phosphodiesterase type 5, an enzyme involved in regulating blood flow. Tadalafil belongs to this class. Its label explains the nitrate danger as the combined effect of nitrates and tadalafil on the nitric oxide/cGMP pathway (cGMP, cyclic guanosine monophosphate, is a signaling molecule) (Cialis label, 2009). That pathway is the signaling route that relaxes blood vessels and lets blood flow increase.

The practical consequence: tadalafil supports the physical side of erectile function, but it is not designed to create desire. PT-141 targets the desire side. That describes mechanism. It is not a promise of results for anyone.

Choosing between daily and as-needed tadalafil is a separate question, covered in our daily vs as-needed tadalafil comparison.

Does PT-141 work for men and women? What the studies show

Brand bremelanotide was approved on the strength of large trials in premenopausal women. The evidence in men is thin: one older randomized trial that used an intranasal form, plus early safety research.

In women, RECONNECT was two identical phase 3, randomized, double-blind, placebo-controlled, multicenter trials. 1,267 premenopausal women with HSDD were randomized to 24 weeks of bremelanotide or placebo (Obstetrics and Gynecology, 2019). Both trials met their prespecified coprimary endpoints. Women who completed them could enter a 52-week open-label extension, which had no placebo comparison. The developer sponsored the trials (Obstetrics and Gynecology, 2019). A 2022 review reports improvements in desire, arousal and orgasm scores versus placebo (Neurology International, 2022). HSDD (hypoactive sexual desire disorder) means persistently low or absent sexual desire and fantasies that cause significant distress or relationship difficulty.

The resulting approval is narrow. Vyleesi is indicated for premenopausal women with acquired, generalized HSDD that is not due to another medical or psychiatric condition, relationship problems or a medication. Its label says it is not indicated for postmenopausal women, for men, or to enhance sexual performance (Vyleesi label, 2024).

In men, the best-known randomized trial, published in 2008, enrolled 342 married men aged 28 to 59 with ED who had not responded to sildenafil. It used intranasal bremelanotide, not an injection (Journal of Urology, 2008). A review of that trial reports that 33.5% of the bremelanotide group versus 8.5% on placebo could attain and maintain an erection sufficient for intercourse (Therapeutic Advances in Urology, 2009). Read that finding with its limits. It is a single, older trial. It used a different formulation from the injection. No FDA approval for men followed. A phase I study of bremelanotide with alcohol included healthy men and women, but it was early safety research, not a test of benefit (Clinical Therapeutics, 2017).

Tadalafil's label position is clearer: as Cialis, it is FDA-approved for ED and for the signs and symptoms of BPH (tadalafil label, DailyMed).

Compounded PT-141 is not FDA-approved. Using it outside the brand label is a clinical judgment, which is why a licensed clinician reviews each intake individually.

PT-141 side effects vs tadalafil side effects

PT-141's most common side effect in the brand trials was nausea, followed by flushing, injection-site reactions and headache. Tadalafil's most common side effects are headache, indigestion, back pain and muscle aches.

PT-141, pooled phase 3 data for Vyleesi versus placebo (Vyleesi label, 2024):

• Nausea: 40.0% vs 1.3%
• Flushing: 20.3% vs 0.3%
• Injection-site reactions: 13.2% vs 8.4%
• Headache: 11.3% vs 1.9%
• Vomiting: 4.8% vs 0.2%

Nausea was highest after the first dose, at 21%, and fell to about 3% with later doses. 13% of participants received anti-nausea medication and 8% stopped because of nausea. Overall, 18% stopped because of side effects, versus 2% on placebo.

Two less obvious effects matter. Blood pressure rose transiently by up to about 6 mmHg systolic and 3 mmHg diastolic (mmHg is the standard blood-pressure unit), peaking 2 to 4 hours after a dose. Heart rate dropped by up to 5 beats per minute. Both usually returned to baseline within 12 hours. Focal hyperpigmentation, meaning darkened patches on the face, gums or breasts, occurred in 1% in phase 3. It was more likely with darker skin and more frequent use, and resolution was not confirmed in every case.

Tadalafil's most common side effects are headache, dyspepsia (indigestion), back pain, myalgia (muscle aches), nasal congestion, flushing and limb pain. Rare but serious warnings include an erection lasting more than 4 hours, sudden loss of vision in one or both eyes (possibly NAION, a loss of blood flow to the optic nerve) and sudden decrease or loss of hearing. Each needs prompt medical care (Cialis label, 2009).

Who should not use PT-141 or tadalafil

PT-141 should not be used by people with uncontrolled high blood pressure or known cardiovascular disease. Tadalafil must not be combined with nitrate medications in any form.

PT-141 (Vyleesi label, 2024):

• Contraindicated with uncontrolled hypertension or known cardiovascular disease, and not recommended at high cardiovascular risk. Blood pressure should be well controlled before and during treatment. That is why a licensed clinician screens blood pressure and heart health before PT-141 is considered.
• Avoid with oral naltrexone products used for alcohol or opioid addiction.
• May slow gastric emptying (how quickly the stomach empties) and affect absorption of oral medicines.
• Stop if pregnancy is suspected. Effective contraception is advised for women who could become pregnant.

A common error is worth correcting. Some clinic and vendor pages describe PT-141 as a better choice for people with blood-pressure or vascular concerns. The label points the opposite way.

Tadalafil (Cialis label, 2009; tadalafil label, DailyMed):

• Must not be combined with any organic nitrate, used regularly or occasionally. That includes nitrate medicines prescribed for chest pain, and recreational "poppers" (amyl nitrite) should also be avoided with tadalafil. Together they can drop blood pressure to unsafe levels.
• Contraindicated with guanylate cyclase stimulators, a drug class used for certain lung and heart conditions, and with hypersensitivity to tadalafil.
• Not for use when sexual activity is inadvisable because of cardiovascular status.
• Alpha blockers, other blood-pressure medicines or substantial alcohol can cause low blood pressure alongside tadalafil.
• Not to be combined with other PDE5 inhibitors.

Neither drug is a substitute for emergency care. Chest pain, fainting, an erection lasting more than 4 hours, or sudden vision or hearing loss need urgent or emergency care.

Can PT-141 and tadalafil be used together?

None of the studies cited here tested PT-141 and tadalafil together, and neither label addresses the combination. Whether either, both or neither is appropriate is a decision for a licensed clinician who knows your full medication list.

Three reasons it is a clinician-only question:

1. The blood-pressure considerations run in opposite directions. PT-141 briefly raises blood pressure. Tadalafil can lower it, especially alongside nitrates, alpha blockers or alcohol. How those effects play out together in one person is not addressed by the studies or labels cited here.
2. The Vyleesi label warns that bremelanotide may slow gastric emptying and affect absorption of oral medicines.
3. The tadalafil label flags combinations with other PDE5 inhibitors and blood-pressure-lowering drugs.

Some online sellers market PT-141 and tadalafil as a "stack". Marketing a combination doesn't make it studied. Never combine them on your own.

How a clinician chooses between PT-141 and tadalafil

A clinician starts with the actual problem, then screens for safety, then matches the drug to an on-label purpose. Sometimes the answer is neither.

1. Clarify the main complaint: low desire, difficulty getting or keeping an erection, or both. The Vyleesi indication itself requires ruling out other causes, such as a medical or psychiatric condition, relationship problems or a medication.
2. Screen for safety. Blood pressure and cardiovascular history are central for PT-141. Nitrate and guanylate cyclase stimulator use is a hard stop for tadalafil. Alpha blockers, other blood-pressure medicines, naltrexone, alcohol use, pregnancy status, and liver or kidney conditions also matter.
3. Match the drug to the problem. Tadalafil fits erectile function or BPH symptoms. PT-141 fits desire concerns, with clear disclosure that compounded PT-141 is not FDA-approved.
4. Consider other causes. Low desire and erection problems can have causes worth evaluating, including hormone levels. For background, see low testosterone symptoms, testing and treatment. Hormone evaluation through New Blue is always a live clinician visit plus lab work.

Questions worth asking a clinician: Is my main issue desire, erection mechanics or both? Does my blood pressure or heart history rule anything out? Do any of my medications interact? Is there something else that should be checked first?

Not everyone qualifies. Eligibility depends on your intake and clinical review, and that's how it should work.

How access works through New Blue

PT-141 and both tadalafil options start with an asynchronous intake that a licensed clinician reviews. New Blue is a technology and administrative services platform. Medical services are provided by independent licensed clinicians; medications are dispensed only if prescribed.

1. Complete a structured online intake. Asynchronous means you answer questions and a licensed clinician reviews them later, rather than meeting live. Some treatments or states may require a live visit.
2. A licensed clinician reviews your history, blood pressure, cardiovascular history and medications, and decides whether a treatment is appropriate.
3. If prescribed, a licensed partner pharmacy ships the medication directly to you. Compounded medications are prepared by state-licensed 503A compounding pharmacies or FDA-registered 503B outsourcing facilities.

PT-141 is injectable only (PT-141 treatment page). Tadalafil comes as a Tadalafil 5 mg daily tablet or a Tadalafil 20 mg troche for as-needed use, a compounded form that dissolves in the mouth. Current pricing is on each treatment page.

Availability varies by state, so check state availability. If treatment isn't appropriate, refunds follow our refund policy. Consultation timing varies by clinician availability. Adults 21+ only. Not for emergencies. New Blue is LegitScript certified.

Frequently Asked Questions

How does compounded PT-141 differ from Vyleesi?

Compounded PT-141 has the same active ingredient as Vyleesi, bremelanotide, but it is a separate compounded product and is not FDA-approved. Vyleesi's approval covers only premenopausal women with acquired, generalized HSDD. Compounded medications are prepared by state-licensed 503A compounding pharmacies or FDA-registered 503B outsourcing facilities.

Is PT-141 stronger than tadalafil?

That is the wrong comparison. PT-141 acts on nervous-system pathways tied to desire, while tadalafil acts on blood flow, so they address different problems rather than being stronger or weaker versions of each other. Which one fits, if either, depends on a licensed clinician's review.

Can women use tadalafil?

Tadalafil's FDA-approved uses are erectile dysfunction and the signs and symptoms of BPH, both conditions in men. Its FDA labeling does not cover use in women. Brand bremelanotide (Vyleesi) is FDA-approved for acquired, generalized HSDD in premenopausal women.

Does PT-141 affect blood pressure?

Yes. According to the Vyleesi label, bremelanotide transiently raises blood pressure and lowers heart rate, usually returning to baseline within 12 hours. It is contraindicated in uncontrolled hypertension and known cardiovascular disease, so a licensed clinician screens blood pressure and heart health before PT-141.

Why can't tadalafil be taken with nitrates?

Tadalafil increases the blood-pressure-lowering effect of nitrates. The label attributes this to their combined effect on the nitric oxide/cGMP pathway, and together they can drop blood pressure to unsafe levels. This applies to any organic nitrate, used regularly or occasionally, and recreational "poppers" (amyl nitrite) should also be avoided.

Do the PT-141 findings in men apply to the injection?

Not directly. The best-known randomized trial in men, published in 2008, used an intranasal form of bremelanotide rather than an injection. It was a single, older trial, and no FDA approval for men followed. Its findings should not be assumed to apply to injectable PT-141.

Sources

1. VYLEESI (bremelanotide injection), for subcutaneous use, Prescribing Information. U.S. National Library of Medicine DailyMed / FDA labeling (Cosette Pharmaceuticals), 2024. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf
2. CIALIS (tadalafil) tablets, Highlights of Prescribing Information. U.S. National Library of Medicine DailyMed / FDA labeling (Eli Lilly; repackaged label), 2009. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ebddb745-81f9-4b25-8739-b2886032ed26
3. Label: TADALAFIL tablet, film coated. U.S. National Library of Medicine DailyMed / FDA labeling, n.d. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=efa03afa-c412-4b31-bf26-7c3a6f7311af
4. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics and Gynecology, 2019. https://pubmed.ncbi.nlm.nih.gov/31599840/
5. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstetrics and Gynecology, 2019. https://pubmed.ncbi.nlm.nih.gov/31599847/
6. Salvage of Sildenafil Failures With Bremelanotide: A Randomized, Double-Blind, Placebo Controlled Study. Journal of Urology, 2008. https://doi.org/10.1016/j.juro.2007.10.063
7. Non-invasive management of primary phosphodiesterase type 5 inhibitor failure in patients with erectile dysfunction. Therapeutic Advances in Urology, 2009. https://pmc.ncbi.nlm.nih.gov/articles/PMC3126073/
8. Bremelanotide for Treatment of Female Hypoactive Sexual Desire. Neurology International, 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC8788464/
9. Phase I Randomized Placebo-controlled, Double-blind Study of the Safety and Tolerability of Bremelanotide Coadministered With Ethanol in Healthy Male and Female Participants. Clinical Therapeutics, 2017. https://pubmed.ncbi.nlm.nih.gov/28189361/

Medical disclaimer: This article is for educational purposes only and is not medical advice. Treatment decisions, including whether any medication is appropriate for you, are made by a licensed clinician based on your intake and clinical review. New Blue Health is a technology and administrative services platform, not a medical provider. Medical services are provided by independent licensed clinicians; medications are dispensed only if prescribed.